To increase the pathophysiological diversity among biofluid biomarkers of neurodegeneration, the Seyfried Lab has developed a novel approach that integrates the global brain network with proteomic analysis of biofluids. Moving forward, integrative analyses that successfully correlate proteomic signatures across brain, CSF, and plasma will prove key for the advancement of clinically relevant network-based biomarkers of disease.